95 related articles for article (PubMed ID: 28837278)
21. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
22. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
23. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Forst T; Bramlage P
Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
[TBL] [Abstract][Full Text] [Related]
24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
Frandsen CS; Madsbad S
Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
[TBL] [Abstract][Full Text] [Related]
26. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic treatment of type 2 diabetes: injectable medications.
Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
Ann Pharmacother; 2015 Jun; 49(6):700-14. PubMed ID: 25802244
[TBL] [Abstract][Full Text] [Related]
28. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
30. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
31. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control.
Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S
Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637
[TBL] [Abstract][Full Text] [Related]
32. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
33. Add-on therapies to metformin for type 2 diabetes.
Shomali M
Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
[TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.
Madsbad S
Eur J Intern Med; 2012 Mar; 23(2):132-6. PubMed ID: 22284242
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic treatment of type 2 diabetes: oral medications.
Tran L; Zielinski A; Roach AH; Jende JA; Householder AM; Cole EE; Atway SA; Amornyard M; Accursi ML; Shieh SW; Thompson EE
Ann Pharmacother; 2015 May; 49(5):540-56. PubMed ID: 25667196
[TBL] [Abstract][Full Text] [Related]
39. [Modern antihyperglycaemic agents--what is the patient benefit?].
Siegmund T
MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585
[No Abstract] [Full Text] [Related]
40. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
Choby B
FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]